Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.40 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.40 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | CASP6 | P55212 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | GPER1 | Q99527 | 1/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4059633 | 0.87 | HPGD (0.38) | ADORA2AADORA3ADORA1NOS3NOS1 | |
| SCHEMBL13608074 | 0.83 | ADORA2A (0.38) | ADORA2AADORA3ADORA2BADORA1PCSK9 | |
| SCHEMBL4059176 | 0.82 | ADRA2A (0.36) | PCSK9NOS3NOS1NOS2EGFR | |
| SCHEMBL4060153 | 0.81 | KDM4E (0.39) | ADORA2AADORA3ADORA2BADORA1MPO | |
| SCHEMBL4054880 | 0.81 | NOS3 (0.42) | ADORA2ANOS3NOS1NOS2FLT3 | |
| SCHEMBL4054333 | 0.81 | GAA (0.43) | NOS3NOS1NOS2EGFR | |
| SCHEMBL4055088 | 0.79 | PRNP (0.42) | ADORA2AADORA3ADORA1NOS3NOS1 | |
| SCHEMBL4053889 | 0.78 | HPGD (0.50) | MPOPCSK9NOS3NOS1NOS2 | |
| SCHEMBL4062519 | 0.78 | TSHR (0.47) | ADORA2AADORA3ADORA2BADORA1NOS3 | |
| SCHEMBL4061234 | 0.78 | NOS3 (0.45) | ADORA2AADORA3ADORA1NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622479-B2 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20050101647-A1 | Bicyclic derivative, its production and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1460067-A1 | BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101647-A1 | Bicyclic derivative, its production and use | ABL1, SRC, PTK2B | ADORA2A 3069/4885ADORA3 3829/4885ADORA2B 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.